Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph‐positive ALL. We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) (n = 19) or lymphoid blast phase of chronic myelogenous leukemia (CML‐LB) (n = 15) with the combination of dasatinib and the hyperCVAD regimen. Prior regimens included hyperCVAD plus imatinib (n = 11, 4 had transplant in first CR), other combination chemotherapy (n = 12), monotherapy with kinase inhibitors other than dasatinib (n = 9), and investigational agents (n = 2). Pretreatment ABL mutations were noted in 10 patients. The overall response rate was 91%, with 24 patients (71%) achieving complete response (CR), and 7(21%) CR with incomplete platelet recovery (CRp). Two patients died during induction and one had progressive disease. Twenty‐six patients (84%) achieved complete cytogenetic remission after one cycle of therapy. Overall, 13 patients (42%) achieved complete molecular response, and 11 patients (35%) had major molecular response (BCR‐ABL/ABL<0.1%). Nine patients proceeded to allogeneic transplantation. Grades 3 and 4 toxicities included hemorrhage, pleural and pericardial effusions and infections. The median follow‐up for patients with CML‐LB is 37.5 months (range, 7–70 months) with a 3‐year overall survival of 70%; 68% remained in CR at 3 years. For ALL patients, the median follow‐up is 52 months (range, 45–59 months) with a 3‐year survival of 26%; 30% remain in CR at 3 years. The combination of HyperCVAD regimen with dasatinib is effective in patients with relapsed Ph‐positive ALL and CML‐LB. Am. J. Hematol. 89:282–287, 2014. © 2013 Wiley Periodicals, Inc.

[1]  M. Baccarani,et al.  Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications , 2012 .

[2]  R. Foà,et al.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[3]  Z. Estrov,et al.  Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy , 2011 .

[4]  Heather L. Mulder,et al.  Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[5]  K. Spiekermann,et al.  Long-Term Outcome of 335 Adult Patients Receiving Different Schedules of Imatinib and Chemotherapy as Front-Line Treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) , 2010 .

[6]  K. Kelly,et al.  A Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogenous Leukemia , 2010 .

[7]  M. Tallman,et al.  Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial , 2010 .

[8]  H. Kantarjian,et al.  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. , 2010, Blood.

[9]  A. Levis,et al.  Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Andreeff,et al.  Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). , 2010 .

[11]  R. Larson,et al.  Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study , 2010, American journal of hematology.

[12]  A. Fielding Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia , 2010, Haematologica.

[13]  J. Esteve,et al.  Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial , 2010, Haematologica.

[14]  Martin C. Müller,et al.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. , 2009, Blood.

[15]  N. Heerema,et al.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Fogarty Highlights from European Hematology Association 14th Annual Congress, Berlin, June 4–7 , 2009 .

[17]  M. Tallman,et al.  Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. , 2009, Blood.

[18]  J. Guralnik,et al.  Prognostic implications of anemia in older adults , 2009, Haematologica.

[19]  O. Ottmann,et al.  Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). , 2009, Hematology. American Society of Hematology. Education Program.

[20]  T. Naoe,et al.  Prospective monitoring of BCR‐ABL1 transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapy , 2008, British journal of haematology.

[21]  H. Kantarjian,et al.  Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors , 2008, Cancer.

[22]  S. Mustjoki,et al.  Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. , 2008, Blood.

[23]  E. Thiel,et al.  Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. , 2008, Blood.

[24]  R. Larson,et al.  Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015). , 2007 .

[25]  J. Radich,et al.  Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. , 2007, Blood.

[26]  J. Oldenburg,et al.  Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). , 2007, Blood.

[27]  J. Cayuela,et al.  Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome – positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study , 2006 .

[28]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[29]  F. Lee,et al.  Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice , 2006, Proceedings of the National Academy of Sciences.

[30]  R. Foà,et al.  The changing scene of adult acute lymphoblastic leukemia , 2006, Current opinion in oncology.

[31]  G. Lenz,et al.  Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL) , 2006 .

[32]  H. Dombret,et al.  Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study , 2006, Leukemia.

[33]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[34]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[35]  T. Naoe,et al.  High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Y. Kodera,et al.  Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease , 2005, Bone Marrow Transplantation.

[37]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[38]  D. Hossfeld,et al.  Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia , 1992, Annals of Hematology.

[39]  H. Kantarjian,et al.  Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.

[40]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[41]  L. Medeiros,et al.  Isothermal multiple displacement amplification: a highly reliable approach for generating unlimited high molecular weight genomic DNA from clinical specimens. , 2004, The Journal of molecular diagnostics : JMD.

[42]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[43]  Steven M Kornblau,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[44]  D. Fabbro,et al.  Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia , 2004, Nature Genetics.

[45]  J. Ford,et al.  Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571) , 2004, Leukemia & lymphoma.

[46]  L. Medeiros,et al.  TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type , 2004, Modern Pathology.

[47]  W. Hofmann,et al.  Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  H. Kantarjian,et al.  The biology and therapy of adult acute lymphoblastic leukemia , 2003, Cancer.

[49]  Yoo-Jin Kim,et al.  Risk factors for adults with Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real‐time quantitative reverse‐transcription polymerase chain reaction , 2003, British journal of haematology.

[50]  H. Gschaidmeier,et al.  Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) , 2002, Leukemia.

[51]  Y. Ikeda,et al.  Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid , 2002, British journal of haematology.

[52]  J. Bourhis,et al.  Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. , 2002, Blood.

[53]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[54]  T. Lipp,et al.  Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. , 2002, Blood.

[55]  L. Foroni,et al.  Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[57]  C. Pui,et al.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.

[58]  Z. Estrov,et al.  Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia , 2000, Leukemia & lymphoma.

[59]  C. Bloomfield,et al.  Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. , 1999, Blood.

[60]  E. Weir,et al.  A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection , 1999, Leukemia.

[61]  Hall,et al.  Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA , 1997, British journal of haematology.

[62]  Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique. , 1996, Blood.

[63]  R. Larson,et al.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. , 1995, Blood.

[64]  J. Craig,et al.  Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. , 1991, Leukemia.

[65]  Walker,et al.  Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. , 1986, Blood.

[66]  J. Burchenal,et al.  Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.